A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers

Charles M. Zelen*, Dennis P. Orgill, Thomas Serena, Robert Galiano, Marissa J. Carter, Lawrence A. DiDomenico, Jennifer Keller, Jarrod Kaufman, William W. Li

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Acellular dermal matrices can successfully heal wounds. This study's goal was to compare clinical outcomes of a novel, open-structure human reticular acellular dermis matrix (HR-ADM) to facilitate wound closure in non-healing diabetic foot ulcers (DFUs) versus DFUs treated with standard of care (SOC). Following a 2-week screening period in which DFUs were treated with offloading and moist wound care, patients were randomised to either SOC alone or HR-ADM plus SOC applied weekly for up to 12 weeks. At 6 weeks, the primary outcome time, 65% of the HR-ADM-treated DFUs healed (13/20) compared with 5% (1/20) of DFUs that received SOC alone. At 12 weeks, the proportions of DFUs healed were 80% and 20%, respectively. Mean time to heal within 12 weeks was 40 days for the HR-ADM group compared with 77 days for the SOC group. There was no incidence of increased adverse or serious adverse events between groups or any adverse events related to the graft. Mean and median graft costs to closure per healed wound in the HR-ADM group were $1475 and $963, respectively. Weekly application of HR-ADM is an effective intervention for promoting closure of non-healing DFUs.

Original languageEnglish (US)
Pages (from-to)307-315
Number of pages9
JournalInternational Wound Journal
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2017

Keywords

  • Diabetic foot ulcers
  • Human acellular dermal tissue
  • Randomised controlled trial
  • Standard of care

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint Dive into the research topics of 'A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers'. Together they form a unique fingerprint.

Cite this